Medical Devices: A Pilot Program to Evaluate a Proposed Globally Harmonized Alternative for Premarket Procedures; Guidance for Industry and FDA Staff; Availability, 68465-68466 [05-22387]
Download as PDF
Federal Register / Vol. 70, No. 217 / Thursday, November 10, 2005 / Notices
• Any unusual condition, such as a
high fever or behavior changes. Signs of
a serious allergic reaction can include
difficulty breathing, hoarseness or
wheezing, hives, paleness, weakness, a
fast heart beat or dizziness.
What should I do?
• Call a doctor, or get the person to
a doctor right away.
• Tell your doctor what happened,
the date and time it happened, and
when the vaccination was given.
• Ask your doctor, nurse, or health
department to report the reaction by
filing a Vaccine Adverse Event
Reporting System (VAERS) form.
Or you can file this report through the
VAERS Web site at https://
www.vaers.hhs.gov, or by calling 1–800–
822–7967.
VAERS does not provide medical
advice.
8. The National Vaccine Injury
Compensation Program
In the event that you or your child has
a serious reaction to a vaccine, a Federal
program has been created to help pay
for the care of those who have been
harmed.
For details about the National Vaccine
Injury Compensation Program, call 1–
800–338–2382 or visit their Web site at
https://www.hrsa.gov/osp/vicp.
9. How can I learn more?
• Ask your immunization provider.
They can give you the vaccine package
insert or suggest other sources of
information.
• Call your local or state health
department.
• Contact the Centers for Disease
Control and Prevention (CDC):
—Call 1–800–232–4636 (1–800–CDC–
INFO).
—Visit CDC’s Web site at https://
www.cdc.gov/flu.
—Vaccine Information Statement.
—Live, Attenuated Influenza Vaccine.
(October 20, 2005)
42 U.S.C. 300aa–26.
Department of Health and Human Services,
Centers for Disease Control and Prevention,
National Immunization Program.
Dated: November 4, 2005.
James D. Seligman,
Associate Director for Program Services,
Centers for Disease Control and Prevention.
[FR Doc. 05–22441 Filed 11–9–05; 8:45 am]
BILLING CODE 4163–18–P
VerDate Aug<31>2005
19:02 Nov 09, 2005
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2001D–0281]
Medical Devices: A Pilot Program to
Evaluate a Proposed Globally
Harmonized Alternative for Premarket
Procedures; Guidance for Industry and
FDA Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance entitled ‘‘A
Pilot Program to Evaluate a Proposed
Globally Harmonized Alternative for
Premarket Procedures; Guidance for
Industry and FDA Staff.’’ The revised
guidance extends the voluntary pilot
premarket review program Summary
Technical Documentation (STED pilot)
until we have received an adequate
number of submissions to evaluate the
STED pilot. The pilot program is
intended for evaluating the utility of an
alternative submission procedure.
DATES: Submit written or electronic
comments on the guidance at any time.
Submit written requests for
single copies on a 3.5’’ diskette of the
guidance document entitled ‘‘A Pilot
Program to Evaluate a Proposed
Globally Harmonized Alternative for
Premarket Procedures; Guidance for
Industry and FDA Staff’’ to the Division
of Small Manufacturers, International,
and Consumer Assistance (HFZ–220),
Center for Devices and Radiological
Health, Food and Drug Administration,
1350 Piccard Dr., Rockville, MD 20850.
Send one self-addressed adhesive label
to assist that office in processing your
request, or fax your request to 301–443–
8818. See SUPPLEMENTARY INFORMATION
section for information on electronic
access to the guidance.
Submit written comments concerning
this guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments.
Identify comments with the docket
number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Harry R. Sauberman, Center for Devices
and Radiological Health (HFZ–480),
Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850,
301–443–4879, or Kenneth J. Cavanaugh
Jr., Center for Devices and Radiological
ADDRESSES:
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
68465
Health (HFZ–450), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 301–443–8517.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of June 26,
2003 (68 FR 38068), FDA announced the
availability of a guidance document
entitled ‘‘A Pilot Program to Evaluate a
Proposed Globally Harmonized
Alternative for Premarket Procedures;
Guidance for Industry and FDA Staff.’’
The guidance document announced a
pilot program for a premarket review
program and encouraged participation
from the medical device industry. The
pilot program is intended to evaluate
the utility of an alternative submission
procedure as described in the draft
STED document prepared by Study
Group 1 of the Global Harmonization
Task Force (GHTF). The document seeks
to harmonize the different requirements
for premarket submissions in various
countries.
The June 26, 2003, guidance and
notice of availability announced that the
pilot program would be in effect for 1
year from the date of publication of the
notice of availability. In the Federal
Register of July 23, 2004 (69 FR 44040),
the pilot program was subsequently
extended until June 25, 2005. FDA has
received no comments on the guidance
issued on June 26, 2003, or the updated
version published on July 23, 2004. In
this revised guidance, FDA is extending
the pilot program until we have
received a sufficient number of
submissions to evaluate the pilot
program. In addition, FDA is updating
the contact information and the
references to the GHTF documents,
along with other minor editorial
changes. The FDA guidance document
is intended to assist the medical device
industry in making submissions to FDA
that use a proposed internationally
harmonized format and content for
premarket submissions, e.g., premarket
approval applications and 510(k)
submissions in the United States. The
revised guidance is a level 2 guidance
under FDA’s good guidance practices
(GGPs) regulation (21 CFR 10.115). FDA
made the guidance available on its Web
site at https://www.fda.gov/cdrh/ode/
guidance/1347.html.
The GHTF is a voluntary group
comprised of medical device regulatory
officials and industry representatives
from the United States, Canada,
Australia, the European Union, and
Japan. The goals of the GHTF include
the following items: (1) Encourage
convergence in regulatory practices with
respect to ensuring the safety,
effectiveness, performance, and quality
E:\FR\FM\10NON1.SGM
10NON1
68466
Federal Register / Vol. 70, No. 217 / Thursday, November 10, 2005 / Notices
of medical devices; (2) promote
technological innovation; and (3)
facilitate international trade. GHTF
provides further information concerning
the structure, goals, and procedures at
the GHTF Web site and can be accessed
at https://ghtf.org.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s Good Guidance
Practice (GGP) regulation (21 CFR
10.115). The guidance represents the
agency’s current thinking on the GHTF
recommendations as related to
premarket submission to FDA. It does
not create or confer any rights for or on
any person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statute and regulations.
III. Electronic Access
To receive a copy of ‘‘A Pilot Program
to Evaluate a Proposed Globally
Harmonized Alternative for Premarket
Procedures; Guidance for Industry and
FDA Staff,’’ by fax call CDRH Facts-OnDemand system at 800–899–0381 or
301–827–0111 from a touch-tone
telephone. Press 1 to enter the system.
At the second voice prompt press 1 to
order a document. Enter the document
number (1347) followed by the pound
sign #. Follow the remaining voice
prompts to complete your request.
To receive ‘‘A Pilot Program to
Evaluate a Proposed Globally
Harmonised Alternative for Premarket
Procedures; Guidance for Industry and
FDA Staff,’’ you may either send a fax
request to 301–443–8818 to receive a
hard copy of the document, or send an
e-mail request to gwa@cdrh.fda.gov to
receive a hard copy or an electronic
copy. Please use the document number
1347 to identify the guidance you are
requesting.
Persons interested in obtaining a copy
of the guidance may also do so by using
the Internet. CDRH maintains an entry
on the Internet for easy access to
information including text, graphics,
and files that may be downloaded to a
personal computer with Internet access.
Updated on a regular basis, the CDRH
home page includes: Device safety
alerts, Federal Register reprints,
information on premarket submissions
(including lists of approved applications
and manufacturers’ addresses), small
manufacturer’s, information on video
conferencing, and electronic
submissions, Mammography Matters,
and other device-related information.
The CDRH web site home page may be
accessed at https://www.fda.gov/cdrh. A
search capability for all CDRH guidance
VerDate Aug<31>2005
19:02 Nov 09, 2005
Jkt 208001
documents is available at https://
www.fda.gov/cdrh/guidance.html.
Guidance documents are also available
on the Division of Dockets Management
Internet site at https://www.fda.gov/
ohrms/dockets.
IV. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Comments
received may be seen in the Division of
Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: November 2, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–22387 Filed 11–9–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Inspector General
Program Exclusions: October 2005
AGENCY:
Office of Inspector General,
HHS.
ACTION:
Notice of program exclusions.
During the month of October 2005,
the HHS Office of Inspector General
imposed exclusions in the cases set
forth below. When an exclusion is
imposed, no program payment is made
to anyone for any items or services
(other than an emergency item or
service not provided in a hospital
emergency room) furnished, ordered or
prescribed by an excluded party under
the Medicare, Medicaid, and all Federal
Health Care programs. In addition, no
program payment is made to any
business or facility, e.g., a hospital, that
submits bills for payment for items or
services provided by an excluded party.
Program beneficiaries remain free to
decide for themselves whether they will
continue to use the services of an
excluded party even though no program
payments will be made for items and
services provided by that excluded
party. The exclusions have national
effect and also apply to all Executive
Branch procurement and nonprocurement programs and activities.
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
Subject name/address
Effective
date
PROGRAM-RELATED CONVICTIONS
ADAIR, KARISTA .....................
LEWISBURG, TN
AUSTIN, HOWARD ..................
OAKDALE, LA
BAILEY, LAWRENCE ...............
SHREVEPORT, LA
BESAW NALEN, KIMBERLY ...
MANCHESTER, NH
BLACK, ANTONIA ....................
FLINT, TX
CONVENIENT DENTAL CARE
CENTER, PC ........................
OKEMOS, MI
DE LA CRUZ, ALFONSO .........
LOS ANGELES, CA
ERLICH, RUSSELL ..................
BROOKLYN, NY
FLORES, SILVIA ......................
ONTARIO, CA
GARCIA, ROSEMARIE ............
SAN DIEGO, CA
HAMILTON BENNETT,
MAISHA ................................
CHICAGO, IL
HAWKINS, KIMBERLY .............
SHAKOPEE, MN
HERNANDEZ, KAREN .............
OKLAHOMA CITY, OK
KATZ, RONALD .......................
OTISVILLE, NY
KEMMETT, BARBARA .............
BRIDGEWATER, MA
KUBRICKY, MARK ...................
OGDEN, UT
LAKHTER, ALEXANDER .........
E STROUDSBURG, PA
LEBEL, ALEXANDER ...............
BROOKLYN, NY
LEEDS, LORI ...........................
SHAKOPEE, MN
LITTLE, MARK .........................
ANTHONY, TX
MALVAREZ, NORBERTO ........
MIAMI, FL
MARTINEZ, CESAR .................
MIAMI, FL
MORAN, PAT ...........................
WICHITA FALLS, TX
SHUMATE, TAMMY .................
LOUISVILLE, KY
UTUK, BECALO .......................
BRYAN, TX
VU, PHOUA ..............................
SAN DIEGO, CA
WALLACE, SHIRLEY ...............
JONESBORO, AR
WILLIAMS-WRIGHT, MYRA ....
MIAMI, FL
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
11/20/2005
FELONY CONVICTION FOR HEALTH CARE
FRAUD
CHAVEZ, WILLIAM ..................
MIAMI, FL
GONZALEZ, DUVIEL ...............
MIAMI, FL
GORRIN, EDDY .......................
MIAMI, FL
KRZYS, PENNY .......................
E:\FR\FM\10NON1.SGM
10NON1
11/20/2005
11/20/2005
11/20/2005
11/20/2005
Agencies
[Federal Register Volume 70, Number 217 (Thursday, November 10, 2005)]
[Notices]
[Pages 68465-68466]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-22387]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2001D-0281]
Medical Devices: A Pilot Program to Evaluate a Proposed Globally
Harmonized Alternative for Premarket Procedures; Guidance for Industry
and FDA Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance entitled ``A Pilot Program to Evaluate a
Proposed Globally Harmonized Alternative for Premarket Procedures;
Guidance for Industry and FDA Staff.'' The revised guidance extends the
voluntary pilot premarket review program Summary Technical
Documentation (STED pilot) until we have received an adequate number of
submissions to evaluate the STED pilot. The pilot program is intended
for evaluating the utility of an alternative submission procedure.
DATES: Submit written or electronic comments on the guidance at any
time.
ADDRESSES: Submit written requests for single copies on a 3.5''
diskette of the guidance document entitled ``A Pilot Program to
Evaluate a Proposed Globally Harmonized Alternative for Premarket
Procedures; Guidance for Industry and FDA Staff'' to the Division of
Small Manufacturers, International, and Consumer Assistance (HFZ-220),
Center for Devices and Radiological Health, Food and Drug
Administration, 1350 Piccard Dr., Rockville, MD 20850. Send one self-
addressed adhesive label to assist that office in processing your
request, or fax your request to 301-443-8818. See SUPPLEMENTARY
INFORMATION section for information on electronic access to the
guidance.
Submit written comments concerning this guidance to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to https://www.fda.gov/dockets/ecomments. Identify comments with the
docket number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Harry R. Sauberman, Center for Devices
and Radiological Health (HFZ-480), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 301-443-4879, or Kenneth J.
Cavanaugh Jr., Center for Devices and Radiological Health (HFZ-450),
Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD
20850, 301-443-8517.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of June 26, 2003 (68 FR 38068), FDA
announced the availability of a guidance document entitled ``A Pilot
Program to Evaluate a Proposed Globally Harmonized Alternative for
Premarket Procedures; Guidance for Industry and FDA Staff.'' The
guidance document announced a pilot program for a premarket review
program and encouraged participation from the medical device industry.
The pilot program is intended to evaluate the utility of an alternative
submission procedure as described in the draft STED document prepared
by Study Group 1 of the Global Harmonization Task Force (GHTF). The
document seeks to harmonize the different requirements for premarket
submissions in various countries.
The June 26, 2003, guidance and notice of availability announced
that the pilot program would be in effect for 1 year from the date of
publication of the notice of availability. In the Federal Register of
July 23, 2004 (69 FR 44040), the pilot program was subsequently
extended until June 25, 2005. FDA has received no comments on the
guidance issued on June 26, 2003, or the updated version published on
July 23, 2004. In this revised guidance, FDA is extending the pilot
program until we have received a sufficient number of submissions to
evaluate the pilot program. In addition, FDA is updating the contact
information and the references to the GHTF documents, along with other
minor editorial changes. The FDA guidance document is intended to
assist the medical device industry in making submissions to FDA that
use a proposed internationally harmonized format and content for
premarket submissions, e.g., premarket approval applications and 510(k)
submissions in the United States. The revised guidance is a level 2
guidance under FDA's good guidance practices (GGPs) regulation (21 CFR
10.115). FDA made the guidance available on its Web site at https://
www.fda.gov/cdrh/ode/guidance/1347.html.
The GHTF is a voluntary group comprised of medical device
regulatory officials and industry representatives from the United
States, Canada, Australia, the European Union, and Japan. The goals of
the GHTF include the following items: (1) Encourage convergence in
regulatory practices with respect to ensuring the safety,
effectiveness, performance, and quality
[[Page 68466]]
of medical devices; (2) promote technological innovation; and (3)
facilitate international trade. GHTF provides further information
concerning the structure, goals, and procedures at the GHTF Web site
and can be accessed at https://ghtf.org.
II. Significance of Guidance
This guidance is being issued consistent with FDA's Good Guidance
Practice (GGP) regulation (21 CFR 10.115). The guidance represents the
agency's current thinking on the GHTF recommendations as related to
premarket submission to FDA. It does not create or confer any rights
for or on any person and does not operate to bind FDA or the public. An
alternative approach may be used if such approach satisfies the
requirements of the applicable statute and regulations.
III. Electronic Access
To receive a copy of ``A Pilot Program to Evaluate a Proposed
Globally Harmonized Alternative for Premarket Procedures; Guidance for
Industry and FDA Staff,'' by fax call CDRH Facts-On-Demand system at
800-899-0381 or 301-827-0111 from a touch-tone telephone. Press 1 to
enter the system. At the second voice prompt press 1 to order a
document. Enter the document number (1347) followed by the pound sign
. Follow the remaining voice prompts to complete your request.
To receive ``A Pilot Program to Evaluate a Proposed Globally
Harmonised Alternative for Premarket Procedures; Guidance for Industry
and FDA Staff,'' you may either send a fax request to 301-443-8818 to
receive a hard copy of the document, or send an e-mail request to
gwa@cdrh.fda.gov to receive a hard copy or an electronic copy. Please
use the document number 1347 to identify the guidance you are
requesting.
Persons interested in obtaining a copy of the guidance may also do
so by using the Internet. CDRH maintains an entry on the Internet for
easy access to information including text, graphics, and files that may
be downloaded to a personal computer with Internet access. Updated on a
regular basis, the CDRH home page includes: Device safety alerts,
Federal Register reprints, information on premarket submissions
(including lists of approved applications and manufacturers'
addresses), small manufacturer's, information on video conferencing,
and electronic submissions, Mammography Matters, and other device-
related information. The CDRH web site home page may be accessed at
https://www.fda.gov/cdrh. A search capability for all CDRH guidance
documents is available at https://www.fda.gov/cdrh/guidance.html.
Guidance documents are also available on the Division of Dockets
Management Internet site at https://www.fda.gov/ohrms/dockets.
IV. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one copy. Comments
are to be identified with the docket number found in brackets in the
heading of this document. Comments received may be seen in the Division
of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: November 2, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-22387 Filed 11-9-05; 8:45 am]
BILLING CODE 4160-01-S